Loading...

Jacek K Pinski, MD, PhD

TitleAssociate Professor of Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressNOR 3446
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3929
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    GlaxoSmithKline2001Fellowship Award
    Johns Hopkins University2001Fellowship Research Award
    American Association for Cancer Research2001Translational Research Award
    2001Stop Cancer Award Special Seed Award
    2002Wright Award
    2002ACS/IRG Award
    2002Whitney Award
    2002Stop Cancer Research Career Development Award

    Collapse Overview 
    Collapse Overview
    After completing a fellowship at the Johns Hopkins Cancer Center in Baltimore, Dr. Pinski came to the Keck School of Medicine at USC as an Assistant Professor of Medicine. A former Research Assistant Professor at the Endocrine, Polypeptide and Cancer Institute at the Tulane University School of Medicine, Dr. Pinski is currently the Co-Director of the USC/Norris Comprehensive Cancer Center’s Prostate Cancer Research Center.

    Dr. Pinski is also a member of the Rehabilitation Research and Development Section for the United States Department of Veteran Affairs. He has received funding for seven research studies and in 2006 was invited to lecture in Austraila at the 3rd Annual Pacific Rim Breast and Prostate Cancer Meeting. Dr. Pinski has had over 60 peer reviewed articles published and has given presentations all across the globe.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski J, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018 Jun 07; 500(3):621-625. PMID: 29679564.
      View in: PubMed
    2. Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):742-749. PMID: 28668277.
      View in: PubMed
    3. Shahabi A, Lewinger JP, Ren J, April C, Sherrod AE, Hacia JG, Daneshmand S, Gill I, Pinski J, Fan JB, Stern MC. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate. 2016 Oct; 76(14):1239-56. PMID: 27272349.
      View in: PubMed
    4. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 10; 14(5):450-456.e1. PMID: 26935231.
      View in: PubMed
    5. Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski J, Stern MC. Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era. Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):E17-22. PMID: 26858782; PMCID: PMC4729570.
    6. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. PMID: 25693195.
      View in: PubMed
    7. Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J. Effects of luteinizing hormone receptor signaling in prostate cancer cells. Prostate. 2015 Feb; 75(2):141-50. PMID: 25393079.
      View in: PubMed
    8. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski J. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. PMID: 25278449.
      View in: PubMed
    9. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski J. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. PMID: 25245366; PMCID: PMC4234307.
    10. Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res. 2014 May 15; 74(10):2857-68. PMID: 24648349; PMCID: PMC4051204.
    11. Ingles SA, Liu SV, Pinski J. LHRH and LHR genotypes and prostate cancer incidence and survival. Int J Mol Epidemiol Genet. 2013; 4(4):228-34. PMID: 24319538; PMCID: PMC3852642.
    12. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski J, Pagliaro LC, Quinn DI, Dorff TB. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. PMID: 24238569.
      View in: PubMed
    13. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski J. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
      View in: PubMed
    14. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski J, Quinn DI. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. PMID: 23785174; PMCID: PMC3783857.
    15. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski J, Quinn DI. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503; PMCID: PMC3375600.
    16. Engel J, Emons G, Pinski J, Schally AV. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012 Jun; 21(6):891-9. PMID: 22577891.
      View in: PubMed
    17. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski J, Quinn DI. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr 18; 4(2):420-41. PMID: 24213318; PMCID: PMC3712699.
    18. Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. Ethnic differences in neuroendocrine expression in prostate cancer tissue. Anticancer Res. 2011 Nov; 31(11):3897-901. PMID: 22110216.
      View in: PubMed
    19. Thara E, Dorff TB, Pinski J, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. PMID: 21621934.
      View in: PubMed
    20. Dorff TB, Pinski J. Advanced prostate cancer: new agents, new questions. Oncology (Williston Park). 2011 May; 25(6):509, 512. PMID: 21717905.
      View in: PubMed
    21. Liu SV, Liu S, Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs. 2011 Jun; 20(6):769-78. PMID: 21449823.
      View in: PubMed
    22. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
      View in: PubMed
    23. Schally AV, Engel JB, Emons G, Block NL, Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv. 2011 Jan; 8(1):11-25. PMID: 21034424.
      View in: PubMed
    24. Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate. 2011 Jun 01; 71(8):892-8. PMID: 21456071.
      View in: PubMed
    25. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski J. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 01; 70(15):1692-700. PMID: 20564320.
      View in: PubMed
    26. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. PMID: 20623636.
      View in: PubMed
    27. Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. PMID: 20670943.
      View in: PubMed
    28. Dorff TB, Goldman B, Pinski J, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019; PMCID: PMC2898710.
    29. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski J. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate. 2009 Jan 01; 69(1):12-23. PMID: 18814146.
      View in: PubMed
    30. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    31. Mori R, Wang Q, Danenberg KD, Pinski J, Danenberg PV. Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate. 2008 Oct 01; 68(14):1555-60. PMID: 18651557.
      View in: PubMed
    32. Chan JS, Beer TM, Quinn DI, Pinski J, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. PMID: 18782306.
      View in: PubMed
    33. Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. PMID: 18095882.
      View in: PubMed
    34. Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski J. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. PMID: 18383880.
      View in: PubMed
    35. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    36. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007 Oct; 38(10):1547-52. PMID: 17640713.
      View in: PubMed
    37. Dorff TB, Quek ML, Daneshmand S, Pinski J. Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. PMID: 17134367.
      View in: PubMed
    38. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski J, Stanczyk FZ, Jones PA, Coetzee GA. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol. 2006 Oct; 26(19):7331-41. PMID: 16980632; PMCID: PMC1592894.
    39. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate. 2006 Aug 01; 66(11):1136-43. PMID: 16652383.
      View in: PubMed
    40. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. PMID: 16697447.
      View in: PubMed
    41. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. PMID: 16221056.
      View in: PubMed
    42. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. PMID: 16020668.
      View in: PubMed
    43. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski J, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. PMID: 15930280.
      View in: PubMed
    44. Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, Pinski J. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology. 2005 May; 65(5):1008-12. PMID: 15882754.
      View in: PubMed
    45. Pinski J, Dorff TB. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005 Apr; 41(6):932-40. PMID: 15808959.
      View in: PubMed
    46. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005 Apr-Jun; 4(2):91-7. PMID: 16105512.
      View in: PubMed
    47. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004 Dec; 172(6 Pt 1):2252-5. PMID: 15538242.
      View in: PubMed
    48. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate. 2004 Nov 01; 61(3):253-9. PMID: 15368468.
      View in: PubMed
    49. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer. 2004 Sep 10; 111(4):508-13. PMID: 15239127.
      View in: PubMed
    50. Horiatis D, Wang Q, Pinski J. A new screening system for proliferation-independent anti-cancer agents. Cancer Lett. 2004 Jul 08; 210(1):119-24. PMID: 15172129.
      View in: PubMed
    51. Jadvar H, Kherbache HM, Pinski J, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003 Dec; 60(6):395-400. PMID: 14690256.
      View in: PubMed
    52. Jadvar H, Pinski J, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. PMID: 12883728.
      View in: PubMed
    53. Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res. 2002 Feb 15; 62(4):986-9. PMID: 11861369.
      View in: PubMed